by C. Brooke Adams, PharmD, BCOP
The cellular therapy landscape continues to evolve beyond hematologic malignancies, now making significant progress in solid tumor treatment.
Certain characteristics seen in solid tumors...
The 2025-2026 respiratory viral season is approaching. With it comes the familiar challenge of protecting our most vulnerable patients — those who have undergone hematopoietic cell...
Hematopoietic cell transplantation can be lifesaving, but it’s also one of the most demanding treatments patients and families will ever face.
ASTCT’s Palliative and Supportive...
by Chelsea Honstain, MS, FNP-C
ASTCT’s Clinical Education Conference will take place Sept. 29-30 in Fort Worth, Texas. Conference attendees will learn about the latest trends in stem cell transplantation and...
by Sita Bhella, MD, MEd, FRCPC
Immune effector cell-associated neurotoxicity syndrome is a complication of chimeric antigen receptor T-cell therapy. The condition is characterized by neurologic symptoms, such as tremors,...
by Jayne Kramer
A new blog post from Jayne Kramer spotlights ASTCT’s upgraded Practice Guidelines mobile app — now featuring a modern interface, enhanced diagnostic tools and improved navigation.